Cutiss
Cutiss AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin is expected to result in a minimally scarring outcome after transplantation. denovoSkin received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.
Tech Stack (23 technologies)
Frequently Asked Questions
What technologies does Cutiss use?+
Cutiss uses 23 technologies including Astra, Elementor, Google Analytics.
What industry is Cutiss in?+
Cutiss operates in the Beauty industry.
Where is Cutiss based?+
Cutiss is headquartered in Switzerland.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026